INT22765

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.34
First Reported 1985
Last Reported 2010
Negated 0
Speculated 1
Reported most in Abstract
Documents 14
Total Number 15
Disease Relevance 3.00
Pain Relevance 5.75

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Ptger2) signal transducer activity (Ptger2)
Anatomy Link Frequency
PGE2 16
nucleus 2
choroid 2
Ptger2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Calcitonin gene-related peptide 74 100.00 Very High Very High Very High
narcan 3 100.00 Very High Very High Very High
diclofenac 1 99.98 Very High Very High Very High
analgesia 3 99.88 Very High Very High Very High
COX2 53 99.80 Very High Very High Very High
acular 4 99.76 Very High Very High Very High
Kappa opioid receptor 4 99.76 Very High Very High Very High
cINOD 3 99.70 Very High Very High Very High
epidural 3 99.68 Very High Very High Very High
agonist 5 98.92 Very High Very High Very High
Disease Link Frequency Relevance Heat
Stress 77 98.52 Very High Very High Very High
INFLAMMATION 94 91.64 High High
Depression 2 91.60 High High
Multiple Sclerosis 132 89.76 High High
Ulcers 3 87.56 High High
Disease 27 86.28 High High
Ganglion Cysts 8 85.88 High High
Headache 30 84.44 Quite High
Pain 22 82.36 Quite High
Nervous System Injury 2 75.00 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In marked contrast, with epidural analgesia, the inhibition of renal secretion of PGE2 is apparent.
Negative_regulation (inhibition) of Localization (secretion) of PGE2 associated with epidural and analgesia
1) Confidence 0.34 Published 1985 Journal Eur J Anaesthesiol Section Abstract Doc Link 3910429 Disease Relevance 0 Pain Relevance 0.39
However, phosphate buffered SIF at pH 6.1 and 6.4 caused a substantial and significant decrease of the PGE2 release, probably due to low-pH block of phospholipases.
Spec (probably) Negative_regulation (decrease) of Localization (release) of PGE2
2) Confidence 0.34 Published 1998 Journal Life Sci. Section Abstract Doc Link 9627103 Disease Relevance 0.24 Pain Relevance 0.56
Treatment in vivo with the NSAID Na-diclofenac lowered PGE2 and IL-1 release and partly reversed the observed reduction of class I and II antigens.
Negative_regulation (lowered) of Localization (release) of PGE2 in PGE2 associated with cinod and diclofenac
3) Confidence 0.18 Published 1990 Journal Agents Actions Section Abstract Doc Link 2327311 Disease Relevance 0.16 Pain Relevance 0.15
The PGE2 release was prevented by selective activation of alpha2-adrenoceptors whereas the CGRP release was not changed.
Negative_regulation (prevented) of Localization (release) of PGE2 in PGE2 associated with calcitonin gene-related peptide
4) Confidence 0.15 Published 2001 Journal Neuroreport Section Abstract Doc Link 11447314 Disease Relevance 0 Pain Relevance 0.56
In contrast, selective kappa-opioid receptor activation diminished electrically evoked release of both CGRP and PGE2.
Negative_regulation (diminished) of Localization (release) of PGE2 in PGE2 associated with kappa opioid receptor and calcitonin gene-related peptide
5) Confidence 0.15 Published 2001 Journal Neuroreport Section Abstract Doc Link 11447314 Disease Relevance 0 Pain Relevance 0.57
In contrast, long-term exposure (3 h) induced a large amount of PGE2 release, which was completely abolished by indomethacin or NS-398.
Negative_regulation (abolished) of Localization (release) of PGE2 in PGE2
6) Confidence 0.12 Published 2006 Journal Neurosci. Lett. Section Abstract Doc Link 16580130 Disease Relevance 0.39 Pain Relevance 0.76
Ketorolac completely abolished the endogenous release of PGE2 in the liver and prevented the induction of immediate-early genes and up-regulation of EP4 mRNA in specific groups of neurons, such as the parvocellular paraventricular nucleus and the A1 catecholaminergic population of cells.
Negative_regulation (abolished) of Localization (release) of PGE2 in nucleus associated with acular
7) Confidence 0.12 Published 2000 Journal J. Neurochem. Section Abstract Doc Link 10800959 Disease Relevance 0 Pain Relevance 0.26
This was accompanied by a significant decrease in both the EC50 of PGE2-evoked glutamate release and the ED50 of PGE2 on brush-evoked allodynia.
Negative_regulation (decrease) of Localization (release) of PGE2 in PGE2
8) Confidence 0.08 Published 2006 Journal Anesthesiology Section Body Doc Link 16436853 Disease Relevance 0 Pain Relevance 0
Location of PGE2 metabolite secretion by choroid plexuses
Negative_regulation (Location) of Localization (secretion) of PGE2 in choroid
9) Confidence 0.05 Published 2008 Journal Cerebrospinal Fluid Res Section Body Doc Link PMC2292143 Disease Relevance 0 Pain Relevance 0
Moreover, NS2028 given alone reduced the basal release of PGE2, indicating that cGMP contributes to the regulation of COX activity.
Negative_regulation (reduced) of Localization (release) of PGE2
10) Confidence 0.04 Published 2009 Journal Mol Pain Section Body Doc Link PMC2731738 Disease Relevance 0.17 Pain Relevance 0.27
At higher concentrations, NS2028 even inhibited basal PGE2 release.
Negative_regulation (inhibited) of Localization (release) of PGE2
11) Confidence 0.03 Published 2009 Journal Mol Pain Section Body Doc Link PMC2731738 Disease Relevance 0.24 Pain Relevance 0.20
Similarly, we have previously demonstrated that administration of supraphysiological doses of 15d-PGJ2 can prevent the release of PGE2 and COX2 increased expression after stress exposure [24].
Negative_regulation (prevent) of Localization (release) of PGE2 associated with stress and cox2
12) Confidence 0.03 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC2958904 Disease Relevance 0.90 Pain Relevance 0.20
It has been suggested that indomethacin induces gastric damage via inhibiting the release of protective factors like cyclooxygenase-1 (COX-1), prostaglandin E2 (PGE2), bicarbonate, and mucus; increasing aggressive factors like acid; and increasing oxidant parameters while decreasing antioxidant parameters.
Negative_regulation (inhibiting) of Localization (release) of PGE2 in PGE2
13) Confidence 0.02 Published 2010 Journal Inflammation Section Abstract Doc Link 20084447 Disease Relevance 0.48 Pain Relevance 0.35
Non-selective and selective COX2 inhibitors suppressed PGE2 and IL-6 release.
Negative_regulation (suppressed) of Localization (release) of PGE2 in PGE2 associated with cox2
14) Confidence 0.01 Published 2005 Journal J. Neurochem. Section Abstract Doc Link 15836625 Disease Relevance 0.42 Pain Relevance 0.67
Baclofen, a specific GABA-B type receptor agonist, had no effect on basal LHRH release, but completely suppressed naloxone-stimulated LHRH and PGE2 secretion.
Negative_regulation (suppressed) of Localization (secretion) of PGE2 in PGE2 associated with gaba, narcan and agonist
15) Confidence 0.01 Published 1989 Journal Endocrinology Section Abstract Doc Link 2544412 Disease Relevance 0 Pain Relevance 0.81

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox